/
Oncology
Patients With Solid Tumors
71
Pipeline Programs↗
56
Active Trials↗
102
Companies Involved↗
Patients With Solid Tumors is a moderately active landscape with 71 programs across 102 companies. The most active players are Shanghai Hengrui Pharmaceutical Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Canwell Biotech Limited. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 129
Phase 240
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
55 of 67 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 100% of 71 pipeline programs.
Analysis
Trial Status
299
clinical trials
Completed176 · 59%
Recruiting36 · 12%
Terminated31 · 10%
Unknown status21 · 7%
Active, not recruiting15 · 5%
Withdrawn10 · 3%
Other10 · 3%
Clinical Trials
Trial Activity
299 trials
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Recruiting·—·Phase 1·NCT02446431·20 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)